With some improvements, clinical cancer registries that exist in every federal state in Germany could be an important new source of comparative data to support submissions for new oncology products undergoing Amnog benefit assessments, according to Volker Vervölgyi, division head of the drug assessment department at IQWiG, Germany’s health technology appraisal institute.
Vervölgyi’s comments follow the publication of a study on using registries to gather better data for the assessments
The Amnog Process
Under the Amnog system, a new product is freely priced in Germany for the first six month after launch. However, the product is then evaluated against a comparator already on the market in terms of the additional benefits it offers. The comparator is selected by the G-BA. Possible ratings include: major benefit, considerable benefit, minor benefit, non-quantifiable benefit, no proven benefit, and less benefit than the comparator.
These ratings are important as they influence pricing negotiations between the pharmaceutical company and health insurers represented by the GKV-SV to agree on the size of the discount on the list price that companies will have to give health insurers
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
